SEC Form 4 · accession 0001209191-15-075197

Aclaris Therapeutics, Inc. · ACRS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director · 10% Owner

Period of report

Oct 13, 2015

Accepted (ET)

Oct 13, 2015 · 1:26 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001557746

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2,F3	Oct 13, 2015	C	1,880,390	—	A	1,880,390	I	By Funds
Common Stock^F3	Oct 13, 2015	P	409,090	$11.00	A	2,289,480	I	By Funds

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A Preferred Stock^F3,F2	—	Oct 13, 2015	C	2,000,000	D	—	—	Common Stock	579,710	I
Series B Preferred Stock^F3,F2	—	Oct 13, 2015	C	2,424,242	D	—	—	Common Stock	702,678	I
Series C Preferred Stock^F3,F2	—	Oct 13, 2015	C	2,063,107	D	—	—	Common Stock	598,002	I

F1The total represents shares received upon conversion of shares of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock.
F2Effective upon the closing of the issuer's initial public offering of its common stock, each share of preferred stock automatically converted into 0.289855 shares of common stock. The preferred stock had no expiration date.
F3The shares are held of record by Sofinnova Venture Partners VIII, L.P. ("SVP VIII"). Sofinnova Management VIII, L.L.C. ("SM VIII") is the general partner of SVP VIII. The Reporting Person is a managing member of SM VIII and may be deemed to share voting and dispositive power over the shares held by SVP VIII. The Reporting Person disclaims beneficial ownership over the shares owned by SVP VIII except to the extent of any pecuniary interest therein.